{"filing":{"accession_number":"0001104659-26-080949","cik":"0001735438","ticker":"MGTX","company_name":"MeiraGTx Holdings plc","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"mgtx-20260630x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1735438/000110465926080949/mgtx-20260630x8k.htm"},"events":[{"id":16308,"run_id":14559,"accession_number":"0001104659-26-080949","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"MeiraGTx entered into a Royalty Note Purchase Agreement with Oberland Capital on June 30, 2026, creating a new direct financial obligation of up to $375 million in senior secured royalty notes. The initial $125 million was funded on June 30, 2026, with additional tranches tied to clinical and regulatory milestones, and the company simultaneously redeemed its prior Perceptive NPA debt agreement, representing a material refinancing of the company's capital structure.","company_name":"MeiraGTx Holdings plc","ticker":"MGTX","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14369,"accession_number":"0001104659-26-080949","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"MeiraGTx entered into a Royalty Note Purchase Agreement on June 30, 2026, creating a new direct financial obligation of up to $375 million in senior secured royalty notes issued by MeiraGTx, LLC. While structured as royalty-based payments rather than traditional debt, the agreement creates a binding financial obligation secured by company assets (cash, equity interests, receivables, property, plant \u0026 equipment, and product-specific assets), with defined repayment terms and default provisions. The initial $125 million funded on June 30, 2026, with additional tranches tied to clinical and regulatory milestones, represents a material capital raise for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14370,"accession_number":"0001104659-26-080949","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 1.02 discloses termination of the Perceptive NPA debt agreement through full redemption on June 30, 2026. While Item 1.02 nominally covers terminations, the supplemental press release reveals the company simultaneously entered into a $400 million strategic investment agreement with Oberland Capital (up to $375 million in non-dilutive royalty funding plus $25 million equity). This represents a material refinancing and new capital structure—the company is replacing one debt obligation with a royalty-based financing arrangement. The royalty funding is economically a debt-like obligation with capped repayment terms, making this a material creation of new direct financial obligations despite the termination framing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14371,"accession_number":"0001104659-26-080949","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"MeiraGTx entered into an agreement with Oberland Capital for up to $400 million in capital, including up to $375 million in non-dilutive royalty funding (structured as a royalty note with capped payments) and up to $25 million in equity. The royalty note creates a direct financial obligation—the company must pay royalties on net sales of specified products (AAV2-hAQP1, bota-vec, and AAV-AIPL1) following regulatory approval. This is a creation of a new direct financial obligation under Item 2.03, distinct from a dilutive equity issuance because the primary funding mechanism ($375M) is non-dilutive royalty-based debt rather than equity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14373,"accession_number":"0001104659-26-080949","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"MeiraGTx entered into a Royalty Note Purchase Agreement with Oberland Capital providing up to $400 million in total capital, including up to $375 million in non-dilutive royalty funding (structured as a royalty note) and up to $25 million in equity. The royalty note represents a direct financial obligation secured by future product revenues, which constitutes a debt-like instrument. While the structure is creative (royalty-based rather than traditional debt), the core transaction is the creation of a new financial obligation backed by capped royalties on three product candidates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":16309,"run_id":14559,"accession_number":"0001104659-26-080949","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"As part of the Oberland Capital strategic investment agreement, MeiraGTx issued up to $25 million in equity securities to Oberland Capital, with Oberland Capital also receiving the right to purchase an additional $15 million in equity, representing a dilutive issuance of unregistered securities.","company_name":"MeiraGTx Holdings plc","ticker":"MGTX","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14372,"accession_number":"0001104659-26-080949","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"MeiraGTx announced a $400 million strategic investment by Oberland Capital that includes \"up to $25 million in equity investment\" and Oberland Capital's right to purchase an additional $15 million in equity. The equity component represents a dilutive issuance of securities to a private investor. While the transaction also includes $375 million in non-dilutive royalty funding, Item 3.02 specifically addresses unregistered sales of equity securities, and the press release explicitly identifies the equity tranches ($10 million initial, $15 million option, and potential additional equity) as part of the overall investment structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14369,"accession_number":"0001104659-26-080949","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"MeiraGTx entered into a Royalty Note Purchase Agreement on June 30, 2026, creating a new direct financial obligation of up to $375 million in senior secured royalty notes issued by MeiraGTx, LLC. While structured as royalty-based payments rather than traditional debt, the agreement creates a binding financial obligation secured by company assets (cash, equity interests, receivables, property, plant \u0026 equipment, and product-specific assets), with defined repayment terms and default provisions. The initial $125 million funded on June 30, 2026, with additional tranches tied to clinical and regulatory milestones, represents a material capital raise for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"MeiraGTx Holdings plc","ticker":"MGTX","filing_date":"2026-07-07"},{"id":14370,"accession_number":"0001104659-26-080949","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The Item 1.02 discloses termination of the Perceptive NPA debt agreement through full redemption on June 30, 2026. While Item 1.02 nominally covers terminations, the supplemental press release reveals the company simultaneously entered into a $400 million strategic investment agreement with Oberland Capital (up to $375 million in non-dilutive royalty funding plus $25 million equity). This represents a material refinancing and new capital structure—the company is replacing one debt obligation with a royalty-based financing arrangement. The royalty funding is economically a debt-like obligation with capped repayment terms, making this a material creation of new direct financial obligations despite the termination framing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"MeiraGTx Holdings plc","ticker":"MGTX","filing_date":"2026-07-07"},{"id":14371,"accession_number":"0001104659-26-080949","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"MeiraGTx entered into an agreement with Oberland Capital for up to $400 million in capital, including up to $375 million in non-dilutive royalty funding (structured as a royalty note with capped payments) and up to $25 million in equity. The royalty note creates a direct financial obligation—the company must pay royalties on net sales of specified products (AAV2-hAQP1, bota-vec, and AAV-AIPL1) following regulatory approval. This is a creation of a new direct financial obligation under Item 2.03, distinct from a dilutive equity issuance because the primary funding mechanism ($375M) is non-dilutive royalty-based debt rather than equity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"MeiraGTx Holdings plc","ticker":"MGTX","filing_date":"2026-07-07"},{"id":14372,"accession_number":"0001104659-26-080949","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"MeiraGTx announced a $400 million strategic investment by Oberland Capital that includes \"up to $25 million in equity investment\" and Oberland Capital's right to purchase an additional $15 million in equity. The equity component represents a dilutive issuance of securities to a private investor. While the transaction also includes $375 million in non-dilutive royalty funding, Item 3.02 specifically addresses unregistered sales of equity securities, and the press release explicitly identifies the equity tranches ($10 million initial, $15 million option, and potential additional equity) as part of the overall investment structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"MeiraGTx Holdings plc","ticker":"MGTX","filing_date":"2026-07-07"},{"id":14373,"accession_number":"0001104659-26-080949","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"MeiraGTx entered into a Royalty Note Purchase Agreement with Oberland Capital providing up to $400 million in total capital, including up to $375 million in non-dilutive royalty funding (structured as a royalty note) and up to $25 million in equity. The royalty note represents a direct financial obligation secured by future product revenues, which constitutes a debt-like instrument. While the structure is creative (royalty-based rather than traditional debt), the core transaction is the creation of a new financial obligation backed by capped royalties on three product candidates.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:10:31.240678+00:00","company_name":"MeiraGTx Holdings plc","ticker":"MGTX","filing_date":"2026-07-07"}]}